iRhythm Technologies Inc. recently presented at the William Blair 45th Annual Growth Stock Conference, highlighting the capabilities of their Zio platform. The company reported a first-quarter 2025 revenue of $158.7 million, marking a 20.3% increase compared to the same period in 2024. iRhythm's patented wearable biosensors, combined with a second-generation, FDA-cleared AI platform, provide a scalable digital solution for cardiac monitoring. The company has posted over 10 million patient reports and curated more than 2.5 billion hours of ECG data since its inception. With over 30% penetration in the U.S. ambulatory cardiac monitoring market and a target market opportunity in prioritized EU and APAC countries, iRhythm aims to address the growing burden of cardiac arrhythmias. You can access the full presentation through the link below.